Aliquam rhoncus mauris, convallis volutpat velit bibendum dui duis ut vulputate amet, ac ipsum nisl convallis ut.
Pulvinar ultrices porta mattis quis lobortis est facilisis purus nunc, sed semper enim dictum sed donec condimentum sodales sed non vel malesuada morbi arcu justo, pretium sagittis hac nisi amet, fermentum nunc.
Blandit auctor felis habitasse aliquet est potenti ut urna eget orci pellentesque commodo vitae.
Magna et nibh quam eu at viverra ut hac faucibus sed cras.
Felis mauris quisque scelerisque ac et, porta sit placerat pharetra, ac sodales vel vitae tincidunt mauris arcu placerat mi quis lorem orci, parturient rutrum.
Tortor platea nunc lorem morbi pellentesque sed enim viverra venenatis, sem pellentesque massa nunc quis lectus.
By addressing this urgent medical need, LUMINATE contributes to healthier, more active lives, ensuring that patients regain mobility without the burden of chronic pain or invasive surgery.
Horizon Europe’s "Good Health & Well-being" (SDG 3)
Enhancing patient-centered healthcare
Improving treatment accessibility for a broader population
The economic burden of osteochondral injuries and osteoarthritis is immense, affecting healthcare systems, insurers, and patients alike. Current treatments, such as joint replacement surgeries, are not only invasive and costly but also lead to long-term expenses due to implant revisions and post-surgical care.
Osteoarthritis costs €76 billion annually in Europe due to treatment, rehabilitation, and productivity loss
Each knee replacement surgery costs €12,000 on average, plus post-operative expenses
50% of younger patients (<50 years) require revision surgeries, doubling healthcare costs
LUMINATE’s innovative bioprinting technology will create new opportunities in:
Egestas pulvinar phasellus id odio viverra pharetra congue est eleifend aenean cras
The LUMINATE project embarks on a journey to redefine osteochondral (OC) tissue regeneration, ensuring that patients suffering from knee cartilage and bone injuries receive groundbreaking, personalized treatment. Through its innovative in situ bioprinting technology, LUMINATE develops a minimally invasive, one-stage solution that could eliminate the need for traditional joint replacement surgeries. Each work package (WP) plays a crucial role in shaping this future, combining cutting-edge bioprinting, biomaterial engineering, artificial intelligence, and clinical validation to bring EndoFLight—the project’s revolutionary bioprinting suite—into reality.